VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ANIKAnika Therapeutics, Inc.
$15.10$202M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksANIKFinancials

Anika Therapeutics, Inc. (ANIK) Financials

30Y historyFree accessUpdated daily

Revenue growth remains erratic with a 13.2% increase in 2026Q1, yet the company continues to struggle with profitability, reporting a negative operating margin of -18.5% for the same period.

ANIK Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue116.26M112.82M119.91M120.79M113.83M147.79M130.46M114.61M105.56M113.42M103.38M93M105.59M75.08M71.36M64.78M55.56M40.14M35.78M30.83M26.84M29.84M26.47M15.4M13.19M11.31M16.34M13.5M13.9M12M1.2M
Revenue Growth %23.22%-5.91%-0.73%6.12%-22.98%13.29%13.83%8.58%-6.93%9.71%11.16%-11.93%40.64%5.22%10.16%16.6%38.42%12.17%16.06%14.86%-10.04%12.73%71.81%16.81%16.57%-30.75%21%-2.88%15.83%900%-64.71%
Cost of Goods Sold48.14M49.01M43.91M38.26M40.61M64.85M61.43M28.75M31.28M27.36M24.03M21.05M20.93M22.77M28.99M26.78M23.83M13.67M13.19M11.88M11.12M11.14M9.95M8.01M8.11M8.23M8.67M5.3M5.2M4.4M700K
COGS % of Revenue-43.44%36.62%31.67%35.67%43.88%47.09%25.08%29.63%24.13%23.24%22.64%19.82%30.32%40.62%41.35%42.89%34.06%36.86%38.54%41.42%37.35%37.59%51.97%61.49%72.74%53.09%39.26%37.41%36.67%58.33%
Gross Profit68.12M63.81M76M82.53M73.22M82.94M69.03M85.86M74.28M86.06M79.35M71.95M84.66M52.32M42.37M37.99M31.73M26.47M22.59M18.95M15.72M18.69M16.52M7.4M5.08M3.08M7.66M8.2M8.7M7.6M500K
Gross Margin %58.59%56.56%63.38%68.33%64.33%56.12%52.91%74.92%70.37%75.87%76.76%77.36%80.18%69.68%59.38%58.65%57.11%65.94%63.14%61.46%58.58%62.65%62.41%48.03%38.51%27.26%46.91%60.74%62.59%63.33%41.67%
Gross Profit Growth %--16.04%-7.92%12.72%-11.72%20.16%-19.61%15.6%-13.69%8.45%10.29%-15.02%61.83%23.47%11.51%19.74%19.89%17.15%19.22%20.52%-15.88%13.16%123.23%45.7%64.71%-59.76%-6.56%-5.75%14.47%1420%-16.67%
Operating Expenses80.38M74.86M81.1M81.69M69.55M80.33M97.35M51.62M52.53M40.33M28.75M23.81M23.22M20M20.12M24.03M24.19M18.73M18.36M12.36M10.3M10.14M10.13M6.8M8.35M10.49M8.65M8.3M5.5M4.4M3.2M
OpEx % of Revenue-66.35%67.63%67.63%61.1%54.35%74.62%45.04%49.76%35.56%27.81%25.6%21.99%26.63%28.19%37.09%43.55%46.66%51.33%40.1%38.36%33.99%38.27%44.17%63.34%92.77%52.93%61.48%39.57%36.67%266.67%
Selling, General & Admin53.95M49.09M55.55M59.92M51.23M74.1M60.06M34.95M34.34M21.54M18.01M14.82M15.07M12.94M14.73M17.86M17.32M10.55M10.97M8M6.68M5.41M6.04M4.21M4.42M6.21M4.19M3M2.7M2.1M2.6M
SG&A % of Revenue-43.51%46.33%49.61%45.01%50.13%46.04%30.49%32.53%18.99%17.42%15.94%14.27%17.23%20.64%27.57%31.17%26.27%30.65%25.94%24.88%18.13%22.83%27.32%33.56%54.93%25.64%22.22%19.42%17.5%216.67%
Research & Development26.42M25.77M25.54M21.76M18.32M27.33M23.43M16.66M18.19M18.79M10.73M8.99M8.14M7.06M5.39M6.17M6.87M8.18M7.4M4.36M3.62M4.73M4.09M2.6M3.93M4.28M3.26M4.2M2M2M0
R&D % of Revenue-22.84%21.3%18.02%16.1%18.49%17.96%14.54%17.23%16.56%10.38%9.66%7.71%9.4%7.55%9.52%12.37%20.38%20.68%14.16%13.47%15.86%15.44%16.85%29.79%37.84%19.96%31.11%14.39%16.67%-
Other Operating Expenses00000-21.09M13.85M00000000000000000001.2M1.1M800K300K600K
Operating Income-12.25M-11.05M-5.1M844K3.67M2.62M-28.32M34.25M21.75M45.73M50.61M48.13M61.45M32.61M19.72M13.97M7.54M5.59M4.23M6.59M5.43M8.55M6.39M595K-3.27M-7.41M-983.37K-100K3.2M3.2M-2.7M
Operating Margin %-10.54%-9.8%-4.25%0.7%3.22%1.77%-21.71%29.88%20.6%40.32%48.95%51.76%58.19%43.43%27.63%21.56%13.57%13.92%11.81%21.37%20.22%28.66%24.14%3.86%-24.83%-65.51%-6.02%-0.74%23.02%26.67%-225%
Operating Income Growth %--116.64%-704.38%-77%40.34%109.23%-182.7%57.47%-52.44%-9.64%5.14%-21.67%88.45%65.39%41.15%85.3%34.92%32.18%-35.84%21.37%-36.53%33.86%973.61%118.17%55.81%-653.61%-883.37%-103.13%0%218.52%-42.11%
EBITDA-6.63M-5.32M3.02M15.06M18.16M16.93M-14.86M40.24M27.66M50.02M54.34M51.91M66.15M37.38M24.24M17.97M10.86M6.88M5.66M7.41M5.81M9.01M7.1M1.6M-2.18M-6.18M214.38K1M4M3.5M-2.1M
EBITDA Margin %-5.7%-4.72%2.52%12.47%15.95%11.46%-11.39%35.11%26.2%44.1%52.56%55.82%62.65%49.79%33.97%27.74%19.54%17.14%15.82%24.02%21.65%30.2%26.82%10.39%-16.53%-54.61%1.31%7.41%28.78%29.17%-175%
EBITDA Growth %-588.58%-276.23%-79.95%-17.05%7.23%213.96%-136.92%45.48%-44.7%-7.95%4.69%-21.53%76.98%54.2%34.9%65.5%57.82%21.56%-23.58%27.44%-35.5%26.94%343.35%173.47%64.72%-2981.35%-78.56%-75%14.29%266.67%-31.25%
D&A (Non-Cash Add-back)5.63M5.73M8.12M14.22M14.49M14.32M13.46M5.99M5.91M4.29M3.73M3.77M4.71M4.77M4.53M4M3.32M1.29M1.43M818.73K384.06K459K710K1.01M1.1M1.23M1.2M1.1M800K300K600K
EBIT-12.25M-11.05M-5.1M844K3.67M-18.48M-14.47M34.25M21.75M45.73M50.61M48.13M61.51M32.61M22.25M13.97M7.54M5.59M4.23M6.59M5.43M9.79M13.82M595K-3.27M-7.41M-983.37K-22.39K2.57M3.2M-2.7M
Net Interest Income0002.31M654K0-302K1.87M1.46M473K263K120K58K-127K-187.78K-182.39K-194.62K-74.48K498.51K2.1M00000000000
Interest Income00-2.31M654K-498K1.87M1.46M473K263K120K58K1860000498.51K2.1M00000000000
Interest Expense00-00-800K000000127.19K5.26M182.39K194.62K4.38M0000000000000
Other Income/Expense2M1.74M2.34M2.31M654K-188K-302K1.87M1.46M473K263K120K58.14K-127K-187.78K-182.39K-194.62K-2.23M498.51K2.1M2.1M1.24M388.71K144K239K662.19K1.17M1.38M700K200K100K
Pretax Income-10.26M-9.31M-2.76M3.16M4.32M2.43M-28.62M36.12M23.21M46.2M50.87M48.25M61.51M32.48M19.53M13.79M7.34M5.51M4.73M8.69M7.53M9.79M6.78M739K-3.03M-6.75M189.49K-100K4.4M3.4M-2.6M
Pretax Margin %-8.82%-8.25%-2.31%2.61%3.8%1.64%-21.94%31.52%21.99%40.74%49.21%51.89%58.25%43.26%27.37%21.28%13.22%13.73%13.21%28.18%28.05%32.82%25.61%4.8%-23.02%-59.66%1.16%-0.74%31.65%28.33%-216.67%
Income Tax818K672K6.06M6.59M2.12M-1.71M-4.64M8.93M4.49M14.39M18.32M17.5M23.19M11.91M7.77M5.32M3.03M1.82M1.1M2.65M2.92M3.9M-4.41M-88K5K9.08K15.94K2.2M100K100K100K
Effective Tax Rate %-7.97%-7.22%-219.39%208.97%49.12%-70.33%16.22%24.72%19.33%31.14%36.02%36.26%37.7%36.65%39.79%38.58%41.22%33.1%23.2%30.53%38.84%39.82%-65.12%-11.91%-0.16%-0.13%8.41%-2200%2.27%2.94%-3.85%
Net Income-11.06M-10.88M-56.38M-82.67M-14.86M4.13M-23.98M27.19M18.72M31.82M32.55M30.76M38.32M20.57M11.76M8.47M4.32M3.69M3.63M6.04M4.6M5.89M11.19M827K-3.04M-6.76M173.55K-2.5M4.3M3.3M-2.7M
Net Margin %-9.52%-9.64%-47.02%-68.44%-13.05%2.8%-18.38%23.73%17.74%28.05%31.48%33.07%36.29%27.4%16.48%13.07%7.77%9.19%10.14%19.58%17.15%19.75%42.28%5.37%-23.05%-59.74%1.06%-18.52%30.94%27.5%-225%
Net Income Growth %80.5%80.7%31.79%-456.34%-459.43%117.24%-188.19%45.25%-41.16%-2.25%5.82%-19.73%86.25%74.99%38.87%96.17%17.04%1.61%-39.87%31.08%-21.87%-47.34%1253.08%127.2%55.01%-3993.68%106.94%-158.14%30.3%222.22%-35%
Net Income (Continuing)-11.08M-9.98M-8.83M-3.44M2.2M4.13M-23.98M27.19M18.72M31.82M32.55M30.76M38.32M20.57M11.76M8.47M4.32M3.69M3.63M6.04M4.6M5.89M11.19M827K-3.04M-6.76M173.55K1.25M3.8M3.3M-2.7M
Discontinued Operations523K-901K-47.56M-79.23M-17.06M00000000000000000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)-0.82-0.76-3.83-5.64-1.020.28-1.691.891.272.112.152.012.511.390.820.620.320.320.320.530.410.520.980.08-0.31-0.680.02-0.240.340.44-0.56
EPS Growth %79.62%80.16%32.09%-452.94%-464.29%116.57%-189.42%48.82%-39.81%-1.86%6.97%-19.92%80.58%69.51%32.26%93.75%0%0%-39.62%29.27%-21.15%-46.94%1125%125.81%54.41%-3985.71%107.29%-170.59%-22.73%178.57%8.2%
EPS (Basic)--0.76-3.83-5.64-1.020.29-1.691.931.302.182.222.062.611.460.890.650.340.320.320.550.430.570.980.08-0.31-0.680.02-0.260.380.60-0.56
Diluted Shares Outstanding13.53M14.34M14.72M14.66M14.56M14.63M14.22M14.37M14.69M15.07M15.12M15.32M15.27M14.83M14.34M13.75M13.65M11.56M11.46M11.45M11.16M11.43M11.42M10.85M9.93M9.93M10.04M10.22M11.01M7.5M4.82M
Basic Shares Outstanding13.53M14.34M14.72M14.66M14.56M14.4M14.22M14.12M14.44M14.57M14.68M14.93M14.68M14.09M13.26M13.06M12.62M11.39M11.31M11.06M10.64M10.41M11.42M9.95M9.93M9.93M9.87M9.74M9.89M5M4.82M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetHealthy
Cash FlowBurning
Top Statement Risk

Persistent negative operating margins

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Volatility Masks Strategic Transition

According to the provided quarterly financial data, Anika's revenue trajectory remains highly erratic, characterized by a 13.2% growth in 2026Q1 following a period of significant contraction, suggesting that the company's shift toward a direct sales model has yet to produce a stable or predictable top-line growth profile.

The inconsistency in quarterly revenue figures indicates that the company is struggling to balance its legacy royalty-based licensing business with the newer, more capital-intensive joint preservation segment. Investors should monitor whether these fluctuations are merely a byproduct of the transition to direct sales or if they reflect a fundamental loss of market share in the competitive viscosupplementation space.

Gross Margin Compression Reflects Mix

As reported in recent financial statements, Anika's gross margin has experienced significant volatility, dipping as low as 3.7% in 2024Q3 before recovering to 64.2% in 2026Q1, which highlights the inherent instability of a business model currently shifting away from high-margin licensing toward lower-margin direct hardware sales.

The wide variance in gross margins suggests that the company's manufacturing capacity utilization is highly sensitive to product mix and potential inventory adjustments. This lack of structural margin consistency warrants further investigation into whether the current 64.2% level is sustainable or if it remains vulnerable to future shifts in the product portfolio.

Operating Leverage Remains Elusive

Based on the income statement data, Anika's operating leverage appears severely constrained, with operating margins remaining negative at -18.5% in 2026Q1, indicating that the company has failed to scale its SG&A expenses efficiently relative to the revenue generated by its direct sales force expansion.

The persistent inability to achieve positive operating income suggests that the current cost structure is too heavy for the company's existing revenue base. Without a clear path to scaling the joint preservation segment, the company may continue to face significant pressure on its bottom line, regardless of improvements in gross margin.

Stock-Based Compensation Masks Operational Deficits

Analysis of the income statement reveals that stock-based compensation, reaching $6.6M in 2026Q1, continues to represent a significant non-cash expense that exacerbates the company's net losses, raising concerns about the quality of earnings and the alignment of management incentives during this period of negative profitability.

The reliance on stock-based compensation in an environment of negative GAAP earnings suggests that the company is effectively diluting shareholders to fund its ongoing operational pivot. Investors should scrutinize whether these compensation levels are appropriate given the lack of progress in achieving sustainable profitability or top-line growth.

Structural Risks to Independent Viability

While management emphasizes the potential of the regenerative solutions portfolio, the financial data suggests a company struggling to compete with larger orthopedic incumbents, as evidenced by the negative operating margins and the high volatility in quarterly performance reported in recent SEC-compliant filings.

Short-term observers may argue that the company's current valuation ignores the potential for an M&A exit, but the fundamental data indicates that the core business is currently value-dilutive. The lack of consistent profitability suggests that the company may be forced to further deplete its cash reserves if it cannot achieve a meaningful inflection in sales productivity soon.

ANIK — Frequently Asked Questions

Quick answers to the most common questions about buying ANIK stock.

What was Anika Therapeutics, Inc.'s (ANIK) revenue in 2025?

For fiscal year 2025, Anika Therapeutics, Inc. (ANIK) reported total revenue of $112.8M. This represents a 9301.6% increase compared to $1.2M in 1996.

Is Anika Therapeutics, Inc. (ANIK) profitable?

Anika Therapeutics, Inc. (ANIK) reported a net loss of $10.9M for the fiscal year ending 2025.

What is Anika Therapeutics, Inc.'s operating profit margin?

Anika Therapeutics, Inc. (ANIK) reported an operating income of $-11.1M, resulting in an operating profit margin of -9.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Anika Therapeutics, Inc.'s gross profit and gross margin?

Anika Therapeutics, Inc. (ANIK) generated $63.8M in gross profit for the year, representing a gross profit margin of 56.6%. This demonstrates the company's core pricing power and production efficiency.